Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model of ibrutinib resistance, in which, after initial treatment response, rela...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 January 2025
|
| In: |
Nature Communications
Year: 2025, Jahrgang: 16, Pages: 1-16 |
| ISSN: | 2041-1723 |
| DOI: | 10.1038/s41467-025-56318-7 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41467-025-56318-7 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41467-025-56318-7 
|
| Verfasserangaben: | Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, Johanne U. Hermansen, Norman Mack, Sibylle Ohl, Verena Kalter, Murat Iskar, Mathias Kalxdorf, Dennis Friedel, Mandy Rettel, Yashna Paul, Ingo Ringshausen, Eric Eldering, Julie Dubois, Arnon P. Kater, Marc Zapatka, Philipp M. Roessner, Eugen Tausch, Stephan Stilgenbauer, Sascha Dietrich, Mikhail M. Savitski, Sigrid S. Skånland, Jeroen Krijgsveld, Peter Lichter, and Martina Seiffert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 193737825X | ||
| 003 | DE-627 | ||
| 005 | 20251209021842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250930s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-025-56318-7 |2 doi | |
| 035 | |a (DE-627)193737825X | ||
| 035 | |a (DE-599)KXP193737825X | ||
| 035 | |a (OCoLC)1559705797 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Arseni, Lavinia |e VerfasserIn |0 (DE-588)1292591919 |0 (DE-627)1848809646 |4 aut | |
| 245 | 1 | 0 | |a Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL |c Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, Johanne U. Hermansen, Norman Mack, Sibylle Ohl, Verena Kalter, Murat Iskar, Mathias Kalxdorf, Dennis Friedel, Mandy Rettel, Yashna Paul, Ingo Ringshausen, Eric Eldering, Julie Dubois, Arnon P. Kater, Marc Zapatka, Philipp M. Roessner, Eugen Tausch, Stephan Stilgenbauer, Sascha Dietrich, Mikhail M. Savitski, Sigrid S. Skånland, Jeroen Krijgsveld, Peter Lichter, and Martina Seiffert |
| 264 | 1 | |c 26 January 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.09.2025 | ||
| 520 | |a Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model of ibrutinib resistance, in which, after initial treatment response, relapse under therapy occurrs with an aggressive outgrowth of malignant cells, resembling observations in patients. A comparative analysis of exome, transcriptome and proteome of sorted leukemic murine cells during treatment and after relapse suggests alterations in the proteasome activity as a driver of ibrutinib resistance. Preclinical treatment with the irreversible proteasome inhibitor carfilzomib administered upon ibrutinib resistance prolongs survival of mice. Longitudinal proteomic analysis of ibrutinib-resistant patients identifies deregulation in protein post-translational modifications. Additionally, cells from ibrutinib-resistant patients effectively respond to several proteasome inhibitors in co-culture assays. Altogether, our results from orthogonal omics approaches identify proteasome inhibition as potentially attractive treatment for chronic lymphocytic leukemia patients resistant or refractory to ibrutinib. | ||
| 650 | 4 | |a Cancer genomics | |
| 650 | 4 | |a Cancer therapeutic resistance | |
| 650 | 4 | |a Chronic lymphocytic leukaemia | |
| 700 | 1 | |a Sigismondo, Gianluca |e VerfasserIn |0 (DE-588)1162971843 |0 (DE-627)102706504X |0 (DE-576)507717538 |4 aut | |
| 700 | 1 | |a Yazdanparast, Haniyeh |e VerfasserIn |0 (DE-588)1161053166 |0 (DE-627)1024462765 |0 (DE-576)506339807 |4 aut | |
| 700 | 1 | |a Hermansen, Johanne U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mack, Norman |e VerfasserIn |0 (DE-588)1275458068 |0 (DE-627)1826932518 |4 aut | |
| 700 | 1 | |a Ohl, Sibylle |e VerfasserIn |0 (DE-588)1292592397 |0 (DE-627)1848810008 |4 aut | |
| 700 | 1 | |a Kalter, Verena |e VerfasserIn |4 aut | |
| 700 | 1 | |a ̇Iskar, Murat |e VerfasserIn |0 (DE-588)1030533385 |0 (DE-627)735446202 |0 (DE-576)378381245 |4 aut | |
| 700 | 1 | |a Kalxdorf, Mathias |e VerfasserIn |0 (DE-588)1264172850 |0 (DE-627)1812851758 |4 aut | |
| 700 | 1 | |a Friedel, Dennis |e VerfasserIn |0 (DE-588)1246387603 |0 (DE-627)1778933017 |4 aut | |
| 700 | 1 | |a Rettel, Mandy |e VerfasserIn |0 (DE-588)1221142607 |0 (DE-627)1738302865 |4 aut | |
| 700 | 1 | |a Paul, Yashna |d 1989- |e VerfasserIn |0 (DE-588)122009448X |0 (DE-627)1736448080 |4 aut | |
| 700 | 1 | |a Ringshausen, Ingo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eldering, Eric |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dubois, Julie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kater, Arnon P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zapatka, Marc |d 1974- |e VerfasserIn |0 (DE-588)128629975 |0 (DE-627)376935782 |0 (DE-576)297249320 |4 aut | |
| 700 | 1 | |a Rößner, Philipp M. |d 1991- |e VerfasserIn |0 (DE-588)1201434629 |0 (DE-627)1685140483 |4 aut | |
| 700 | 1 | |a Tausch, Eugen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stilgenbauer, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dietrich, Sascha |d 1979- |e VerfasserIn |0 (DE-588)136406300 |0 (DE-627)694354635 |0 (DE-576)301003408 |4 aut | |
| 700 | 1 | |a Savitski, Mikhail M. |e VerfasserIn |0 (DE-588)1213301939 |0 (DE-627)1703816242 |4 aut | |
| 700 | 1 | |a Skånland, Sigrid S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krijgsveld, Jeroen |e VerfasserIn |0 (DE-588)1163292125 |0 (DE-627)1027502032 |0 (DE-576)507882474 |4 aut | |
| 700 | 1 | |a Lichter, Peter |d 1957- |e VerfasserIn |0 (DE-588)1096366282 |0 (DE-627)856749915 |0 (DE-576)468019049 |4 aut | |
| 700 | 1 | |a Seiffert, Martina |d 1965- |e VerfasserIn |0 (DE-588)115760326 |0 (DE-627)691570736 |0 (DE-576)171620747 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature Communications |d [London] : Springer Nature, 2010 |g 16(2025), Artikel-ID 1041, Seite 1-16 |h Online-Ressource |w (DE-627)626457688 |w (DE-600)2553671-0 |w (DE-576)331555905 |x 2041-1723 |7 nnas |a Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL |
| 773 | 1 | 8 | |g volume:16 |g year:2025 |g elocationid:1041 |g pages:1-16 |g extent:16 |a Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-025-56318-7 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41467-025-56318-7 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20250930 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 115760326 |a Seiffert, Martina |m 115760326:Seiffert, Martina |d 50000 |e 50000PS115760326 |k 0/50000/ |p 26 |y j | ||
| 998 | |g 1096366282 |a Lichter, Peter |m 1096366282:Lichter, Peter |d 50000 |e 50000PL1096366282 |k 0/50000/ |p 25 | ||
| 998 | |g 1163292125 |a Krijgsveld, Jeroen |m 1163292125:Krijgsveld, Jeroen |d 50000 |e 50000PK1163292125 |k 0/50000/ |p 24 | ||
| 998 | |g 136406300 |a Dietrich, Sascha |m 136406300:Dietrich, Sascha |d 910000 |d 910100 |d 50000 |e 910000PD136406300 |e 910100PD136406300 |e 50000PD136406300 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 21 | ||
| 998 | |g 1201434629 |a Rößner, Philipp M. |m 1201434629:Rößner, Philipp M. |d 50000 |e 50000PR1201434629 |k 0/50000/ |p 18 | ||
| 998 | |g 128629975 |a Zapatka, Marc |m 128629975:Zapatka, Marc |d 50000 |e 50000PZ128629975 |k 0/50000/ |p 17 | ||
| 998 | |g 1246387603 |a Friedel, Dennis |m 1246387603:Friedel, Dennis |d 910000 |d 912000 |e 910000PF1246387603 |e 912000PF1246387603 |k 0/910000/ |k 1/910000/912000/ |p 10 | ||
| 998 | |g 1162971843 |a Sigismondo, Gianluca |m 1162971843:Sigismondo, Gianluca |d 910000 |d 912000 |e 910000PS1162971843 |e 912000PS1162971843 |k 0/910000/ |k 1/910000/912000/ | ||
| 998 | |g 1292591919 |a Arseni, Lavinia |m 1292591919:Arseni, Lavinia |d 700000 |d 711000 |e 700000PA1292591919 |e 711000PA1292591919 |k 0/700000/ |k 1/700000/711000/ |p 1 |x j | ||
| 999 | |a KXP-PPN193737825X |e 4777774759 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Lavinia","role":"aut","display":"Arseni, Lavinia","family":"Arseni"},{"family":"Sigismondo","display":"Sigismondo, Gianluca","role":"aut","given":"Gianluca"},{"family":"Yazdanparast","display":"Yazdanparast, Haniyeh","role":"aut","given":"Haniyeh"},{"display":"Hermansen, Johanne U.","family":"Hermansen","given":"Johanne U.","role":"aut"},{"display":"Mack, Norman","family":"Mack","role":"aut","given":"Norman"},{"given":"Sibylle","role":"aut","family":"Ohl","display":"Ohl, Sibylle"},{"given":"Verena","role":"aut","display":"Kalter, Verena","family":"Kalter"},{"display":" ̇Iskar, Murat","family":" ̇Iskar","role":"aut","given":"Murat"},{"display":"Kalxdorf, Mathias","family":"Kalxdorf","role":"aut","given":"Mathias"},{"family":"Friedel","display":"Friedel, Dennis","role":"aut","given":"Dennis"},{"given":"Mandy","role":"aut","family":"Rettel","display":"Rettel, Mandy"},{"family":"Paul","display":"Paul, Yashna","given":"Yashna","role":"aut"},{"display":"Ringshausen, Ingo","family":"Ringshausen","given":"Ingo","role":"aut"},{"role":"aut","given":"Eric","family":"Eldering","display":"Eldering, Eric"},{"display":"Dubois, Julie","family":"Dubois","role":"aut","given":"Julie"},{"family":"Kater","display":"Kater, Arnon P.","given":"Arnon P.","role":"aut"},{"family":"Zapatka","display":"Zapatka, Marc","role":"aut","given":"Marc"},{"given":"Philipp M.","role":"aut","family":"Rößner","display":"Rößner, Philipp M."},{"given":"Eugen","role":"aut","display":"Tausch, Eugen","family":"Tausch"},{"display":"Stilgenbauer, Stephan","family":"Stilgenbauer","given":"Stephan","role":"aut"},{"role":"aut","given":"Sascha","display":"Dietrich, Sascha","family":"Dietrich"},{"given":"Mikhail M.","role":"aut","family":"Savitski","display":"Savitski, Mikhail M."},{"display":"Skånland, Sigrid S.","family":"Skånland","given":"Sigrid S.","role":"aut"},{"family":"Krijgsveld","display":"Krijgsveld, Jeroen","given":"Jeroen","role":"aut"},{"role":"aut","given":"Peter","display":"Lichter, Peter","family":"Lichter"},{"role":"aut","given":"Martina","family":"Seiffert","display":"Seiffert, Martina"}],"id":{"doi":["10.1038/s41467-025-56318-7"],"eki":["193737825X"]},"recId":"193737825X","relHost":[{"id":{"issn":["2041-1723"],"zdb":["2553671-0"],"eki":["626457688"]},"recId":"626457688","physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLLNature Communications","origin":[{"publisherPlace":"[London] ; [London]","dateIssuedDisp":"[2010]-","publisher":"Springer Nature ; Nature Publishing Group UK"}],"note":["Gesehen am 13.06.24"],"pubHistory":["2010-"],"title":[{"title_sort":"Nature Communications","title":"Nature Communications"}],"part":{"volume":"16","text":"16(2025), Artikel-ID 1041, Seite 1-16","extent":"16","pages":"1-16","year":"2025"},"language":["eng"]}],"name":{"displayForm":["Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, Johanne U. Hermansen, Norman Mack, Sibylle Ohl, Verena Kalter, Murat Iskar, Mathias Kalxdorf, Dennis Friedel, Mandy Rettel, Yashna Paul, Ingo Ringshausen, Eric Eldering, Julie Dubois, Arnon P. Kater, Marc Zapatka, Philipp M. Roessner, Eugen Tausch, Stephan Stilgenbauer, Sascha Dietrich, Mikhail M. Savitski, Sigrid S. Skånland, Jeroen Krijgsveld, Peter Lichter, and Martina Seiffert"]},"physDesc":[{"extent":"16 S.","noteIll":"Illustrationen"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 30.09.2025"],"origin":[{"dateIssuedDisp":"26 January 2025","dateIssuedKey":"2025"}],"title":[{"title":"Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL","title_sort":"Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL"}]} | ||
| SRT | |a ARSENILAVILONGITUDIN2620 | ||